BioNexus Gene Lab Corp
BGLC
查看详细走势图
2.110USD
+0.120+6.03%
收盘 02/06, 16:00（美东）报价延迟15分钟
3.79M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+6.03%
5天
-18.75%
1月
-47.38%
6月
-62.72%
今年开始到现在
-46.58%
1年
-45.19%
查看详细走势图
TradingKey BioNexus Gene Lab Corp股票评分
单位: USD 更新时间: 2026-02-06操作建议
BioNexus Gene Lab Corp当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名204/392位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
BioNexus Gene Lab Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
BioNexus Gene Lab Corp亮点
亮点风险
BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
业绩增长期
公司处于发展阶段，最新年度总收入9.51M美元
利润高增长
公司净利润处于行业前列，最新年度总收入9.51M美元
估值高估
公司最新PE估值-1.65，处于3年历史高位
活跃度降低
近期活跃度降低，过去20天平均换手率-0.96
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
BioNexus Gene Lab Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
BioNexus Gene Lab Corp简介
BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
公司代码BGLC
公司BioNexus Gene Lab Corp
CEOTan (Lee Su-Leng)
网址https://www.bionexusgenelab.com/
相关品种
